Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
D-Glucuronic acid
108
CHF
CHF 108.00
In stock
CDX-G0020-G02525 gCHF 108.00
CDX-G0020-G05050 gCHF 162.00
| Product Details | |
|---|---|
| Synonyms | Glucosiduronic acid; D-GlcA |
| Product Type | Chemical |
| Properties | |
| Formula |
C6H10O7 |
| MW | 194.14 |
| CAS | 03.12.6556 |
| RTECS | LZ8836600 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in water (50mg/ml) or DMSO (2mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | AEMOLEFTQBMNLQ-QIUUJYRFSA-N |
| Smiles | O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Glucuronic acid is a water soluble sugar acid formed by oxidation of the C-6 carbon of glucose. Glucuronic acid is a common building block of proteoglycans and glycoglycerolipids and a key intermediate metabolite of the uronic acid pathway. It can be used as a reference compound to quantify glucuronic acid in urine sample. It also has been shown to act on toll-like receptor 4 to aggravate both acute and chronic inflammatory conditions as well as increasing the perceived severity of pain in patients with chronic pain conditions, via up-regulation of the production and release of endogenous inflammatory signaling molecules within the body.
Product References
(1) J.J. Burns, et al.; JPET 129, 132 (1960) | (2) T. Kishikawa, et al.; Chem. Pharm. Bull. 14, 1354 (1966) | (3) U. Lindahl, et al.; BBRC 46, 985 (1972) | (4) A.O. El-Nezhawy, et al.; Arch. Pharm. 344, 648 (2011) | (5) A.O. El-Nezhawy, et al.; Med. Chem. 7, 624 (2011) | (6) S.S. Lewis, et al.; Brain Behav. Immun. 30, 24 (2013) | (7) S. Marasini, et al.; J. Nanosci. Nanotechnol. 18, 6333 (2018)